Hepatotoxicity of immune checkpoint inhibitors: What is Currently Known.

Caiyun Zheng Shunmin Huang Meimei Lin Baohui Hong Ruping Ni Hengfen Dai Xiuqin Lin Jing Yang

Published in: Hepatology communications (2023)

The highest incidence of hepatotoxicity and fatality was observed with triple therapy. The overall incidence of hepatotoxicity was similar between different dual regimens. For immune checkpoint inhibitor monotherapy, the overall risk of immune-mediated hepatotoxicity related to CTLA-4 inhibitors did not differ significantly from that of PD-1 inhibitors. There was no direct relationship between the risk of liver injury and drug dose, whether monotherapy or combination therapy was used.

Keyphrases

drug induced
liver injury
combination therapy
risk factors
adverse drug
open label
emergency department
randomized controlled trial
bone marrow
mesenchymal stem cells